As of Thursday close, Elanco Animal Health Incorporated’s (NYSE:ELAN) stock was down -$0.2, moving down -1.61 percent to $12.20. The average number of shares traded per day over the past five days has been 4,386,360 shares. 3 times new highs have been achieved over the past 5 days, with a $0.53 gain in that time frame. In the last twenty days, the average volume was 5,020,150, while in the previous 50 days, it was 5,787,006.
Since last month, ELAN stock rose 4.01%. Shares of the company fell to $11.25 on 08/18/23, the lowest level in the past month. A 52-week high of $16.14 was reached on 02/02/23 after having rallying from a 52-week low of $7.88. Since the beginning of this year, ELAN’s stock price has dropped by -0.16% or -$0.02, and marked a new high 10 times. However, the stock has declined by -24.41% since its 52-week high.
ELAN stock investors should be aware that Elanco Animal Health Incorporated (ELAN) stock had its last reported insider trading activity 171 days ago on Mar 14. HOOVER R DAVID, the Director of the company, purchased of 5,000 shares for $9.55 on Mar 14. It resulted in a $47,750 investment by the insider. HOOVER R DAVID added 5,000 shares at an average price of $9.46 on Mar 13. The insider now owns 160,000 shares following the transaction. On Mar 10, PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought 15,000 shares at $9.60 apiece. The transaction was valued at $143,972.
Valuation Metrics
The stock’s beta is 1.01. Besides these, the trailing price-to-sales (P/S) ratio of 1.37, the price-to-book (PB) ratio of 0.81.
Financial Health
In the three months ended June 29, Elanco Animal Health Incorporated’s quick ratio stood at 1.50, while its current ratio was 2.80, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.81, and the total debt-to-equity ratio was 0.82. On the profitability front, the trailing twelve-month gross margin is 57.30% percent. In the year ended June 29, EBITDA margin amounted to 24.17%, whereas operating margins totaled 5.10%. Based on annual data, ELAN earned $2.5 billion in gross profit and brought in $4.41 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 1.50%. Return on equity (ROE) for the past 12 months was -1.40%.
In Elanco Animal Health Incorporated’s quarter-end financial report for June 29, it reported total debt of $6.02 billion. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. ELAN’s revenue fell -11.35% to $1.26 billion during the quarter, while net income inched up to $1.06 billion. While analysts expected Elanco Animal Health Incorporated to report $0.05 quarterly earnings, the actual figure was $0.18 per share. During the quarter, the company generated $195.0 million in EBITDA. The liabilities of Elanco Animal Health Incorporated were 8.38 billion at the end of its most recent quarter ended June 29, and its total debt was $6.06 billion. The value of shareholders’ equity is $492.68 million.
Technical Picture
This quick technical analysis looks at Elanco Animal Health Incorporated’s (ELAN) price momentum. With a historical volatility rate of 30.58%, the RSI 9-day stood at 56.25% on 31 August.
With respect to its five-day moving average, the current Elanco Animal Health Incorporated price is up by +4.54% percent or $0.53. At present, ELAN shares trade +4.18% above its 20-day simple moving average and +33.33% percent above its 100-day simple moving average. However, the stock is currently trading approximately +22.12% above its SMA50 and -9.70% below its SMA200.
Stochastic coefficient K was 81.46% and Stochastic coefficient D was 78.00%, while ATR was 0.37. Given the Stochastic reading of 66.90% for the 14-day period, the RSI (14) reading has been calculated as 56.89%. As of today, the MACD Oscillator reading stands at 0.40, while the 14-day reading stands at 0.51.
Analyst Ratings
Barclays upgraded its rating on Elanco Animal Health Incorporated (NYSE: ELAN) to an Overweight in a note to investors on April 20, 2023. The analysts firm previously had an Equal weight rating on the stock.Elanco Animal Health Incorporated (ELAN) has been rated Hold by analysts. According to 1 brokerage firm, ELAN is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate Elanco Animal Health Incorporated stock as buy, with 3 recommending it as overweight.
With a median target price of $13.50, the current consensus forecast for the stock is $9.50 – $19.00. Based on these forecasts, analysts predict Elanco Animal Health Incorporated (ELAN) will achieve an average price target of $13.94.
